Blog

EsoCap investment offer and lunch invitation

 



EsoCap Investment Offer

EsoCap AG (‘EsoCap’) is offering an equity investment of CHF 10 million in a private placement at a price of CHF 28 per share, representing a pre-money valuation of CHF 77.5 million.

The funds from this offering will be used for the roll-out of the international patent portfolio, preparation of the pivotal Phase III clinical trial, interactions with regulatory authorities in the US and Europe, industrial scale-up and production of clinical trial material for the Phase III clinical trial.  

EsoCap is in the process of preparing a commercial transaction with a major pharmaceutical company specialising in gastroenterology and cancer. EsoCap is in the process of preparing a commercial transaction with a major pharmaceutical company specialising in gastroenterology and cancer. EsoCap's technology platform has the potential to unlock breakthrough treatment options for over 370 million patients in a market worth more than USD 10bn. EsoCap is thus an extremely attractive target for commercial transactions.

 

About EsoCap

EsoCap AG is a privately funded joint stock company based in Basel, Switzerland.

EsoCap has successfully developed a unique, highly sophisticated platform technology with multiple applications for local drug therapy in patients with severe oesophageal diseases.

EsoCap's technology guarantees a significantly longer contact time of drugs (small molecules, peptides, biologics, and encapsulated mRNA treatment principles) in the oesophagus, resulting in a safe and highly effective treatment outcome.

The lead candidate ESO-101 has received Orphan Drug Designation from the US Food & Drug Administration (FDA) for the treatment of eosinophilic oesophagitis (EoE). EsoCap recently successfully completed the double-blind, randomised, placebo-controlled Phase II ACESO study with ESO-101 in five countries, demonstrating the clinical applicability of the platform technology.

EsoCap has a strong and diversified intellectual property position as well as a highly complementary team and development infrastructure.

For more information, please visit www.esocapbiotech.com
 

Contact:

Isabelle Racamier

CEO

isabelle.racamier@esocapbiotech.com

Phone: +43 699 149 50 300

 

Investor lunch presentation

On October 24th, 2024 there will be a lunch presentation in Zurich at Club zum Rennweg.
If you like to attend, RSVP here or send an email.
We are looking forward to seeing you.

Sign up

Recommended events

For registration and discount information, visit the page links

 

Global Alternative Investing Summit

Oct 7, 2024, London

Quant Strats Europe 2024

Oct 8, 2024, London

European CLO Summit

Oct 8, 2024, London

LATAM Fintech Forum

Oct 8 - 9, 2024, Miami

LATAM Investment Convergence Summit

Oct 8 - 9, 2024, Miami

18th NextGen Payments & RegTech Forum

Oct 10 - 11, 2024, Athens

European Private Credit Summit

Oct 9, 2024, London

Going Global & The Business Show - LA

Oct 9 - 11, 2024, Los Angeles

OpenBanking Expo

Oct 15, 2024, London

Family Office & Private Wealth Management Forum

Oct 15 - 17, 2024, Napa

India Blockchain Summit 2024

Oct 19, 2024, New Delhi

The Ticket Price of Natural Disasters

Oct 22, 2024, Zurich

Esco Cap Lunch Presentation

Oct 24, 2024, Zurich

Fintech Without Borders Forum

Oct 25, 2024, London

World Business Outlook Awards 2024

Nov 2, 2024, Bangkok

Connected Germany 2024

Nov 5 - 6, 2024, Munich

19th NextGen Payments & RegTech Forum

Nov 6 - 7, 2024, Limassol

Endowment & Foundation Forum

Nov 7 - 8, 2024, Boston

BANKING 4.0 AND BANKING INNOVATION

Nov 7 - 8, 2024, Berlin

Art and Fintech Startup Award Night

Nov 9, 2024, Zurich

Going Global

Nov 13 - 14, 2024, London

View more events
 
 


Newsletters   Health   Technology   Tools   Investing